The Global Parkinson's Disease Therapeutics Market to grow from USD 4,985.67 Million in 2019 to USD 7,522.33 Million by 2025, at a Compound Annual Growth Rate (CAGR) of 7.09%.
Market Segmentation & Coverage:
The research report categorizes the Parkinson's Disease Therapeutics Market to forecast the revenues and analyze the trends in each of the following segments:
"The Intestinal Infusion is projected to witness the highest growth during the forecast period"
Based on Type, the Parkinson's Disease Therapeutics Market studied across Intestinal Infusion, Oral, Subcutaneous, and Transdermal. The Oral commanded the largest size in the Parkinson's Disease Therapeutics Market in 2019, followed by the Intestinal Infusion. On the other hand, the Intestinal Infusion expected to grow at the fastest CAGR during the forecast period, followed by the Transdermal.
"The Anticholinergic is projected to witness the highest growth during the forecast period"
Based on Drug Class, the Parkinson's Disease Therapeutics Market studied across Anticholinergic, Carbidopa/Levodopa, COMT Inhibitor, Dopamine Receptor Agonist, and MAO Inhibitor. The Carbidopa/Levodopa commanded the largest size in the Parkinson's Disease Therapeutics Market in 2019, followed by the Anticholinergic. On the other hand, the Anticholinergic expected to grow at the fastest CAGR during the forecast period, followed by the Carbidopa/Levodopa.
"The Online Pharmacy is projected to witness the highest growth during the forecast period"
Based on Distribution Channel, the Parkinson's Disease Therapeutics Market studied across Hospital Pharmacy, Online Pharmacy, and Retailer Pharmacy. The Hospital Pharmacy commanded the largest size in the Parkinson's Disease Therapeutics Market in 2019, followed by the Retailer Pharmacy. On the other hand, the Online Pharmacy expected to grow at the fastest CAGR during the forecast period, followed by the Retailer Pharmacy.
"The Clinic is projected to witness the highest growth during the forecast period"
Based on End Use, the Parkinson's Disease Therapeutics Market studied across Clinic and Hospital. The Hospital commanded the largest size in the Parkinson's Disease Therapeutics Market in 2019, followed by the Clinic. On the other hand, the Clinic expected to grow at the fastest CAGR during the forecast period, followed by the Hospital.
"The Asia-Pacific is projected to witness the highest growth during the forecast period"
Based on Geography, the Parkinson's Disease Therapeutics Market studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas region surveyed across Argentina, Brazil, Canada, Mexico, and United States. The Asia-Pacific region surveyed across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, South Korea, and Thailand. The Europe, Middle East & Africa region surveyed across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom. The Europe, Middle East & Africa commanded the largest size in the Parkinson's Disease Therapeutics Market in 2019, followed by the Americas. On the other hand, the Asia-Pacific expected to grow at the fastest CAGR during the forecast period, followed by the Americas.
Market Dynamics:
The factors attributing to the growth of the market are development of new therapies and minimally invasive new devices and growing aging population and the associated increase in the prevalence of parkinson’s disease. However, some factors such as availability of alternative treatments may hinder the market growth. The Parkinson's Disease Therapeutics Market expected to showcase the opportunities such as potential for pharmaceutical companies due to patent expiry, strong drug pipeline under clinical research, and increasing pace of r&d by the government in the u.s., the uk, and other countries for parkinson's disease management. Soon market may face the possible challenges in the growth due to sales erosion due to expiry of patents. However, the key players in the market are putting regressive efforts to provide innovative offerings and benchmark strategies in the market.
Global Parkinson's Disease Therapeutics Market: Market Dynamics
Cumulative Impact of COVID-19:
COVID-19 is an incomparable global public health emergency that has affected almost every industry, so for and, the long-term effects projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlaying COVID-19 issues and potential paths forward. The report is delivering insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecast, considering the COVID-19 impact on the market.
360iResearch Competitive Strategic Window:
The 360iResearch Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies. The Competitive Strategic Window helps the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. During a forecast period, it defines the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth.
360iResearch FPNV Positioning Matrix:
The 360iResearch FPNV Positioning Matrix evaluates and categorizes the vendors in the Parkinson's Disease Therapeutics Market on the basis of Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.
Company Usability Profiles:
The Parkinson's Disease Therapeutics Market is highly competitive and characterized by the presence of a large number of international and regional players in the market. The market has witnessed increased competition between vendors based on the pricing model, technology differentiation, brand name, quality of service, price differentiation, and technical expertise.
The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Parkinson's Disease Therapeutics Market, including Abbvie, Inc., ACADIA Pharmaceuticals, Inc., Amneal Pharmaceuticals, Inc., Apotex, Inc., Bausch Health Companies, Inc., Boehringer Ingelheim International GmbH, Cipla, Inc., Daiichi Sankyo Company, H. Lundbeck A/S, Mylan N.V., Novartis AG, Orion Corporation, Par Pharmaceutical by Endo International PLC, Sun Pharmaceutical Industries Limited, Teva Pharmaceutical Industries Ltd., UCB S.A., and WOCKHARDT.
